Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Virpax Pharmaceuticals, Inc. - Common Stock (NQ:VRPX)

0.6695 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Virpax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Virpax Pharmaceuticals Announces Leadership Transition
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Gerald W. Bruce Appointed President and CEO of Novvae™ Pharmaceuticals
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studies
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses
From Altasciences
Via Business Wire
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Updates on Litigation
From Virpax Pharmaceuticals
Via Business Wire
Virpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent Developments
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals, Inc. to Ring NASDAQ Closing Bell on July 24, 2023
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Files Provisional Patent Application for Intranasal Delivery
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke Council
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Announces CFO Transition
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminar
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference May 10-11, 2023
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Engages Dr. Pardeep Gupta to Assist in Development of Company’s Lead Asset, Probudur™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Reports on Progress of Envelta™
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Reports 2022 Year-End Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)
From Virpax Pharmaceuticals
Via Business Wire
Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering Efforts
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324)
From Virpax Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.